Dr Shubhra Sinha

Eedara, B. B., Fan, C., Sinha, S., Khadka, P., & Das, S. C. (2023). Inhalable combination powder formulations for treating latent and multidrug-resistant tuberculosis: Formulation and in vitro characterization. Pharmaceutics, 15, 2354. doi: 10.3390/pharmaceutics15092354

Journal - Research Article

Montgomerie, I., Bird, T. W., Palmer, O. R., Mason, N. C., Pankhurst, T. E., Lawley, B., … Harfoot, R., … Sinha, S., … on behalf of the VAANZ Group. (2023). Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience. Advance online publication. doi: 10.1016/j.isci.2023.106256

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection. Pharmaceutics, 15, 2229. doi: 10.3390/pharmaceutics15092229

Journal - Research Article

Adhikari, B. R., Sinha, S., Gordon, K. C., & Das, S. C. (2022). Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for Pseudomonas aeruginosa lung infection. International Journal of Pharmaceutics, 621, 121799. doi: 10.1016/j.ijpharm.2022.121799

Journal - Research Article

Adhikari, B. R., Sinha, S., Lyons, N., Pletzer, D., Lamont, I., Gordon, K. C., & Das, S. C. (2022). Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation. European Journal of Pharmaceutics & Biopharmaceutics. Advance online publication. doi: 10.1016/j.ejpb.2022.10.005

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones Mateu, M. E., & Das, S. C. (2022). Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder. Pharmaceutics, 14(7), 1432. doi: 10.3390/pharmaceutics14071432

Journal - Research Article

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. European Journal of Pharmaceutics & Biopharmaceutics, 162, 1-11. doi: 10.1016/j.ejpb.2021.02.011

Journal - Research Article

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model. International Journal of Pharmaceutics, 597, 120345. doi: 10.1016/j.ijpharm.2021.120345

Journal - Research Article

Momin, M. A. M., Adhikari, B. R., Sinha, S., Larson, I., & Das, S. C. (2021). Roflumilast powders for chronic obstructive pulmonary disease: Formulation design and the influence of device, inhalation flow rate, and storage relative humidity on aerosolization. Pharmaceutics, 13, 1254. doi: 10.3390/pharmaceutics13081254

Journal - Research Article

Momin, M. A. M., Rangnekar, B., Larson, I., Sinha, S., & Das, S. C. (2019). Dry powder formulation combining bedaquiline with pyrazinamide for latent and drug-resistant tuberculosis. Advanced Powder Technology, 30(11), 2473-2482. doi: 10.1016/j.apt.2019.07.016

Journal - Research Article

Momin, M. A. M., Rangnekar, B., Sinha, S., Cheung, C.-Y., Cook, G. M., & Das, S. C. (2019). Inhalable dry powder of Bedaquiline for pulmonary tuberculosis: In vitro physiochemical characterization, antimicrobial activity and safety studies. Pharmaceutics, 11(10), 502. doi: 10.3390/pharmaceutics11100502

Journal - Research Article

Momin, M. A. M., Sinha, S., Tucker, I. G., & Das, S. C. (2019). Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Drug Development & Industrial Pharmacy, 45(8), 1321-1331. doi: 10.1080/03639045.2019.1609494

Journal - Research Article

Rangnekar, B., Momin, M. A. M., Eedara, B. B., Sinha, S., & Das, S. C. (2019). Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International Journal of Pharmaceutics, 570, 118689. doi: 10.1016/j.ijpharm.2019.118689

Journal - Research Article

Eedara, B. B., Rangnekar, B., Sinha, S., Doyle, C., & Cavallaro, A. (2018). Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. European Journal of Pharmaceutical Sciences, 118, 216-226. doi: 10.1016/j.ejps.2018.04.003

Journal - Research Article

Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., Sinha, S., & Das, S. C. (2018). Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. International Journal of Pharmaceutics, 541(1-2), 26-36. doi: 10.1016/j.ijpharm.2018.02.026

Journal - Research Article

Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017). Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. International Journal of Pharmaceutics, 528(1-2), 107-117. doi: 10.1016/j.ijpharm.2017.06.004

Journal - Research Article

Sinha, S., Kuo, C.-Y., Ho, J. K., White, P. J., Jazayeri, J. A., & Pouton, C. W. (2017). A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration. Vaccine, 35(40), 5115-5122. doi: 10.1016/j.vaccine.2017.08.014

Journal - Research Article